recombinant human thrombopoietin

ApprovedSmall molecule

SShenyang Sunshine Pharmaceutical Co., LTD.

recombinant human thrombopoietin is one of 95 small molecule programs targeting Thrombocytopenia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThrombocytopeniaActive, not recruiting

Breast CancerActive, not recruiting

Immune ThrombocytopeniaActive, not recruiting

ThrombocytopeniaApproved

Active, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Immune ThrombocytopeniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

recombinant human thrombopoietin

SShenyang Sunshine Pharmaceutical Co., LTD.

Approved

1 2

DATROWAY

Daiichi Sankyo

Preclinical

4 3

Megace

Bristol-Myers Squibb

Preclinical

4 4

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Spravato

WWim Janssens

Preclinical

2 7

Zinecard

CChildren's Oncology Group

Preclinical

2 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Chantix

PPrism Pharmaceuticals

Preclinical

1 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

MDS

NCT07400341

Clinical

Trials by Indication[1]

Thrombocytopenia3 trials

Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT02267993·58 enrolled

Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy

Terminated·CChinese Society of Lung Cancer·Phase 2/3·NCT01319669·11 enrolled

A Phase Ib Clinical Study for rhTPO in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease

Unknown status·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 1·NCT05193201·54 enrolled

Immune Thrombocytopenia3 trials

Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia

Unknown status·SShandong University·Phase 3·NCT03492515·90 enrolled

Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Withdrawn·SShandong University·Phase 3·NCT01734057

A Study of Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia

Unknown status·PPeking University People's Hospital··NCT04214951·100 enrolled

Transplantation1 trial

Recombinant Human Thrombopoietin for Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation

Unknown status·HHongnan Mo·Phase 1/2·NCT03014102·50 enrolled

MDS1 trial

Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT07400341·66 enrolled

Breast Cancer1 trial

Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer

Completed·NNorthwestern University·Phase 1/2·NCT00006225

8 more indications

Impairment1 trial

The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment

Unknown status·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 1·NCT03673215·58 enrolled

Recurrent or Refractory Solid Tumors1 trial

Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors

Completed·CChildren's Oncology Group·Phase 1·NCT00003597·16 enrolled

Romiplostim N011 trial

A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin

Not yet recruiting·SShandong University·Phase 3·NCT06440824·60 enrolled

POI1 trial

Effects of Recombinant Human Thrombopoietin on Platelet Levels in ICU Patients

Unknown status·NNanfang Hospital, Southern Medical University·Phase 4·NCT05217719·178 enrolled

Dexamethasone1 trial

rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP

Completed·SShandong University·Phase 3·NCT01734044·158 enrolled

Chemotherapy1 trial

Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy

Completed·SSt. Jude Children's Research Hospital·Phase 1/2·NCT00187109·40 enrolled

ITP1 trial

An Investigation of rhTPO With Different Frequencies in the Management of ITP

Completed·SShandong University·Phase 3·NCT02139501·48 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 4·NCT01379391·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for recombinant human thrombopoietin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — recombinant human thrombopoietin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for recombinant human thrombopoietin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenyang Sunshine Pharmaceutical Co., LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SShenyang Sunshine Pharmaceutical Co., LTD.

recombinant human thrombopoietin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Thrombocytopenia3 trials

Immune Thrombocytopenia3 trials

Transplantation1 trial

MDS1 trial

Breast Cancer1 trial

Impairment1 trial

Recurrent or Refractory Solid Tumors1 trial

Romiplostim N011 trial

POI1 trial

Dexamethasone1 trial

Chemotherapy1 trial

ITP1 trial

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News